Clinical Trial Update: Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B [Phase 3]

View source ↗

Summary

Phase 3 trial of Marzeptacog Alfa (Activated) for Hemophilia A or B with inhibitors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia with Inhibitor

Drugs mentioned

• Marzeptacog Alfa (Activated) (Marzeptacog alfa activated)

Snippet

Sponsor: Catalyst Biosciences | Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Status: TERMINATED